OnCo

JEB (carboplatin, etoposide, bleomycin)

Checked 2026-09-09

Malignant extracranial germ cell tumours in children (UK Children's Cancer Study Group), a carboplatin-based alternative to cisplatin regimens

Also called JEB.

One cycle

every 21 days × 4-6 · about 12 weeks in total
178141521Carboplatin: 600 mg/m² (or dosed to GFR), IntravenousCarboplatinEtoposide: 120 mg/m², IntravenousEtoposideBleomycin: 15 mg/m², IntravenousBleomycin
21-day cycle × 4-6 (two beyond marker normalisation) (about 12 weeks)Intravenous

Components

DrugDoseRouteDays
Carboplatin
Cytotoxic chemotherapy (platinum)
600 mg/m² (or dosed to GFR)IVD2
Etoposide
Topoisomerase II inhibitor (podophyllotoxin derivative)
120 mg/m²IVD1-3
Bleomycin
Glycopeptide antibiotic (DNA-cleaving)
15 mg/m²IVD3
Cycles
4-6 (two beyond marker normalisation)
21-day cycle
Emetogenicity
High (>90%)
G-CSF
Not routine

Notes

  • Carboplatin replaced cisplatin to spare children's hearing and kidneys, with cure rates comparable to cisplatin-based regimens in this study.
  • Bleomycin is given once per cycle, less often than in adult BEP.

Used in

Source

Mann (UKCCSG GC2), JCO 2000: carboplatin, etoposide and bleomycin for children's germ cell tumours

Reference doses for a typical adult from the cited protocol or label. Doses are adjusted for renal and hepatic function, age, performance status and prior toxicity, and institutional protocols vary. Verify against the current label and your local protocol before treating. Not medical advice.